High Rates of Anti-αIIbβ3 Antibodies Produced by a Glanzmann Thrombasthenia Patient after First and Unique Red Blood Cells Administration.
Glanzmann thrombasthenia
Immunization
Platelet antibody
Red blood cells administration
rFVIIa
αIIbβ3
Journal
Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
02
2022
accepted:
01
07
2022
pubmed:
15
9
2022
medline:
3
2
2023
entrez:
14
9
2022
Statut:
ppublish
Résumé
Immunization against the platelet αIIbβ3 glycoprotein due to blood transfusion represents one of the most severe complications in Glanzmann thrombasthenia (GT) disease. Anti-αIIbβ3 isoantibodies development may lead to ineffective platelet transfusion and can, in case of pregnancy, cross the placenta leading to fetal thrombocytopenia. We describe here the case of a girl with type I GT who developed high rates of anti-αIIbβ3 isoantibodies after first and unique blood transfusion. Surprisingly, this patient had only received red blood cell concentrates and immunization was presumably stimulated by the residual presence of platelets in concentrates. This study emphasizes the need for regular anti-αIIbβ3 antibodies screening in GT, even though patients have never been previously transfused with platelet concentrates.
Identifiants
pubmed: 36103848
pii: 000526224
doi: 10.1159/000526224
doi:
Substances chimiques
Isoantibodies
0
Platelet Glycoprotein GPIIb-IIIa Complex
0
Platelet Membrane Glycoproteins
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-46Informations de copyright
© 2022 S. Karger AG, Basel.